Author:
Jin Jiefu,Krishnamachary Balaji,Mironchik Yelena,Kobayashi Hisataka,Bhujwalla Zaver M.
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. American Cancer Society. Breast cancer facts and figures 2015–2016. Atlanta: American Cancer Society, Inc. (2015) Available at: http://www.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures (Accessed: Feburary 17th, 2016).
2. Carey, L., Winer, E., Viale, G., Cameron, D. & Gianni, L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7, 683–692 (2010).
3. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N Engl J Med 363, 1938–1948 (2010).
4. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429–4434 (2007).
5. Dent, R. A. et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 15, R88 (2013).
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献